Results showing corneal endothelial cell regeneration with sovesudil (starting phase III clinical trial for glaucoma; also known as PHP-201) and PHP-961 was presented at the Association for Research in Vision and Ophthalmology Annual Meeting May 1st – 5th, 2022 (ARVO 2022). This study was conducted at Hallym University in collaboration...
피에이치파마, ‘ROCK 저해제’ 녹내장 2상 “안압 낮춰＂
정상안압 녹내장 2상서 '소베수딜' 안압 낮추고 부작용 개선 'best-in-class' ROCK 저해제로 개발 가능성 올해말 국내 3상 계획 및 파트너링 추진 http://www.biospectator.com/view/news_view.php?varAtcId=13929
PH파마, 베스트인 클래스 녹내장 치료제 개발 청신호
국내 환자 많은 정상안압녹내장 환자 대상 2상, 통계적 유의성 달성 지난 5월 식약처로부터 3상 승인 받고 두 파트로 나눠 임상 준비 중 http://www.hitnews.co.kr/news/articleView.html?idxno=35435
Sovesudil phase II study published in Acta Ophthalmologica
Results testing sovesudil (PHP-201) in normal-tension glaucoma patients in a clinical study was published in the journal Acta Ophthalmologica. This study was funded by pH Pharma and was conducted at 15 clinical centres in South Korea. The study demonstrated the potential of sovesudil in providing intraocular pressure (IOP) reduction in...
Sovesudil neuroprotection results presented at WGC Annual Meeting
Results showing neuroprotection with sovesudil (PHP-201) was presented at the World Glaucoma Congress Annual Meeting June 30th - July 3rd, 2021 (WGC 2021). This study was conducted at The University of Melbourne as a collaboration with pH Pharma. The study demonstrated the potential of sovesudil in providing neuroprotection to neurons...
[Notice] Information on protection and measures for holders (shareholders) of sovereigns subject to electronic securities conversion
pH Pharma Develops New Drugs through Synergy between US and Korea
Sanjeev Satyal, Head of R&D of pH PhamaImplement new technology and culture from U.S.Basic research for new drug candidate in KoreaDeveloping glaucoma and NASH treatments(For more information, please refer to the link below)https://www.hankyung.com/it/article/202003033648i
pH Pharma IND approval for “Alpha-1 Antitrypsin Deficiency treatment” Phase 2 clinical trial in Europe
PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.(For more information, please refer to the link below)https://www.edaily.co.kr/news/read?newsId=02745366625637392
The reason why the US FDA was able to quickly approve the new ADC drug, Enhertu
New ADC deals between big pharma made recentlypH Pharma builds toxin library for ADC development(For more information, please refer to the link below)http://www.medigatenews.com/news/1001974809
New stock issuance notice